PHOENIX--(BUSINESS WIRE)--Global Cancer Diagnostics Inc. today announced the start of the final validation study of its new blood test for early detection of lung cancer. The study will complete the requisite analyses and data evaluation needed to validate the test and introduce it to the market. Global Cancer Diagnostics (GCDx) plans to offer this new test on a nationwide basis.
Clinical Studies to date demonstrated that The Lung Cancer Test for Early Detection™ successfully detected Stages 1 and 2 lung cancer with a high degree of accuracy in both men and women. The results generated in this final validation study are fully expected to be consistent with previous findings and produce positive clinical performance.
Help employers find you! Check out all the jobs and post your resume.
